Current Report Filing (8-k)
05 1월 2021 - 1:15AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 4, 2021 (January 4, 2021)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
125
Cambridge Park Drive, Suite 301,Cambridge
|
|
MA
02140
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code +1 (617) 430 5222
245
First Street, Suite 1800, Cambridge, MA 02142
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name of
each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
Luckwel
Pharmaceuticals Inc. (the “Company”) has changed its address and is now headquartered at 125 Cambridge Park Drive,
Suite 301,Cambridge, MA 02140. Its telephone number has been changed to +1 (617) 430 5222.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
Date:
January 4, 2021
|
|
/s/ Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Luckwel Pharmaceuticals Inc (GM) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Luckwel Pharmaceuticals Inc. News Articles